Dextech Medical Third Quarter 2025 Earnings: kr0.067 loss per share (vs kr0.077 loss in 3Q 2024)
Dextech Medical (NGM:DEX) Third Quarter 2025 Results
Key Financial Results
- Revenue: kr515.0k (down 59% from 3Q 2024).
- Net loss: kr1.24m (loss narrowed by 12% from 3Q 2024).
- kr0.067 loss per share (improved from kr0.077 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dextech Medical shares are up 3.4% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Dextech Medical that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:DEX
Dextech Medical
Engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.
Flawless balance sheet very low.
Market Insights
Community Narratives
